Background & Objectives: Regarding the high prevalence of hyperlipidemia in the world especially in Iran, finding suitable and effective treatment seems justified. Metronidazole is the only drug that is used as an antiparasital and antiprotozoal agent. Researchers have found that oral dose of 750 mg/day has a suitable absorption, is widely distributed in the tissues and reaches to a blood level of 4-6 mg/ml. Despite its suitable efficiency, a few clinical trial have been conducted in this regard. This study was designed as such to examine the effect of metronidazole on lowering blood lipids.

  Methods: The present research was performed as a clinical trial without control, on 50 patients. All the patients filled out a special form (to show their satisfaction) as well as a questionnaire. Metronidazole was given with a daily dose of 750 mg for a week. 20 patients with no complaint continued their drug consumption for another seven days. Lipid parameters such as plasma total lipid, total cholesterol, and triglyceride were measured in both groups. The data were collected and analyzed with SPSS software using t-test.

  Results: Measuring the serum level of lipids indicated that the mean total plasma lipid and total cholesterol decreased significantly compared to their level before taking the drug (p<0.01). The findings also showed a similar decrease in plasma TG level (p<0.001). In the patients who continued the drug consumption in the second week, the serum level of lipids under study showed more decrease compared to their levels in the first week which was statistically significant (p<0.01). Liver tests indicated that the functioning of liver has not changed during drug consumption.

  Conclusion: Using 750 mg of metronidazole per day exerts a significant decrease in lipids fractions in a short time. Most cases of hyperlipidemia require a long-term treatment, hence metronidazole can be effectively used in the treatment of short-term hyperlipidemia.